TP53 and cancer: Both MSS cohorts showed a high rate of cancers (≥40%) with targeted deletion events at several loci previously associated with CRC, such as 18q21.1–18q21.2 (which includes SMAD2, SMAD4, DCC) and 17p13.1 (p53) (Table S4A in File S1).